Cargando…

P04-18. Comparison of HIV neutralization assays for use in vaccine research and clinical trials, phase II: results from the NeutNet working group

Detalles Bibliográficos
Autores principales:	Scarlatti, G, Alcami, J, Bongertz, V, Fenyö, E, Heath, A, Heyndrickx, L, Holmes, H, Jansson, M, Lopalco, L, Malnati, M, Montefiori, D, Moog, C, Morris, L, Osmanov, S, Polonis, V, Ramaswamy, M, Sattentau, Q, Schuitemaker, H, Wrin, T
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767947/ http://dx.doi.org/10.1186/1742-4690-6-S3-P46

Ejemplares similares

International Network for Comparison of HIV Neutralization Assays: The NeutNet Report II
por: Heyndrickx, Leo, et al.
Publicado: (2012)

International Network for Comparison of HIV Neutralization Assays: The NeutNet Report
por: Fenyö, Eva Maria, et al.
Publicado: (2009)

NEUT status and prospects
por: Hayato, Yoshinari
Publicado: (2022)

Electron-nucleus scattering in the NEUT event generator
por: Dolan, S., et al.
Publicado: (2023)

Neutralizing antibodies elicited in rabbits by patient-derived Env trimer immunization
por: Heyndrickx, L, et al.
Publicado: (2012)

P07-04. HIV-1 evolution in mother to child transmission and pediatric disease progression
por: Dispinseri, S, et al.
Publicado: (2009)

Widespread Non-Canonical Epigenetic Modifications in MMTV-NeuT Breast Cancer()()
por: Felts, Sara J., et al.
Publicado: (2015)

Role of NEUT-X & NEUT-Y in picking up megaloblastic anaemia on peripheral blood & in differentiating from other macrocytic anaemia
por: Goel, Shalini, et al.
Publicado: (2017)

P04-50 LB. Prevalence of cross-reactive HIV-1 neutralizing activity in HIV-1 infected patients with rapid or slow disease progression
por: van Gils, MJ, et al.
Publicado: (2009)

Microenvironment, Oncoantigens, and Antitumor Vaccination: Lessons Learned from BALB-neuT Mice
por: Conti, Laura, et al.
Publicado: (2014)

NEUT-SFL in Patients with COVID-ARDS: A Novel Biomarker for Thrombotic Events?
por: Stiel, Laure, et al.
Publicado: (2021)

Selected HIV-1 Env Trimeric Formulations Act as Potent Immunogens in a Rabbit Vaccination Model
por: Heyndrickx, Leo, et al.
Publicado: (2013)

P04-46. Broadly cross-neutralizing activity in plasma of HIV-1 and HIV-2 infected individuals
por: Fenyö, E, et al.
Publicado: (2009)

MMTV-NeuT/ATTAC mice: a new model for studying the stromal tumor microenvironment
por: Yuan, Hongyan, et al.
Publicado: (2018)

P04-20. Humoral immune response in acute HIV-1 infection
por: Mainetti, L, et al.
Publicado: (2009)

P04-12. Characterization of leukopak PBMC phenotypes and biotypes for optimal performance in HIV-1 neutralization assays
por: Brown, BK, et al.
Publicado: (2009)

Correction: MMTV-NeuT/ATTAC mice: a new model for studying the stromal tumor microenvironment
por: Yuan, Hongyan, et al.
Publicado: (2018)

P04-19. Analysis of the binding of multiple clades of HIV-1 by a modified virus capture assay
por: Peachman, K, et al.
Publicado: (2009)

P04-23. HIV-1 neutralization is impacted by the PBMC donor used for both virus growth and target cells, and the effects are neutralization reagent-specific
por: Wieczorek, L, et al.
Publicado: (2009)

A hypoxic signature marks tumors formed by disseminated tumor cells in the BALB-neuT mammary cancer model
por: Msaki, Aichi, et al.
Publicado: (2016)

P04-36. HIV-1-speficic antibody dependant cellular cytotoxicity (ADCC) médiated by primary NK cells
por: Delaporte, M, et al.
Publicado: (2009)

P04-29. HIV-1 neutralizing antibodies inhibit plasmacytoid dendritic cells infection
por: Lederle, A, et al.
Publicado: (2009)

The Potential Role of Neutrophil-Reactive Intensity (NEUT-RI) in the Diagnosis of Sepsis in Critically Ill Patients: A Retrospective Cohort Study
por: Mantovani, Elena Maria Alessandra, et al.
Publicado: (2023)

P04-47. High-titer autologous and heterologous neutralizing antibody activity in acute SIV-infection
por: Schweighardt, B, et al.
Publicado: (2009)

P04-28. Breadth and magnitude of neutralizing antibody responses in subjects infected with HIV-1 subtype D or recombinants in Rakai district, Uganda
por: Eller, L, et al.
Publicado: (2009)

PD-L1(+)NEUT, Foxp3(+)Treg, and NLR as New Prognostic Marker with Low Survival Benefits Value in Hepatocellular Carcinoma
por: Zhou, Lin, et al.
Publicado: (2021)

Resistance of MMTV-NeuT/ATTAC mice to anti-PD-1 immune checkpoint therapy is associated with macrophage infiltration and Wnt pathway expression
por: Yuan, Hongyan, et al.
Publicado: (2022)

P04-49 LB. Adaptation of HIV-1 envelope glycoprotein to humoral immunity at a population level
por: Bunnik, EM, et al.
Publicado: (2009)

P04-52 LB. The importance of well-defined HIV-1 neutralization assays
por: Balla-Jhagjhoorsingh, SS, et al.
Publicado: (2009)

P04-34. Identification of 4E10-like antibodies in plasma of an HIV-1 CRF02_AG infected patient with broad neutralizing activity using peptide phage libraries
por: Dieltjens, T, et al.
Publicado: (2009)

P04-27. Monoclonal neutralizing antibodies inhibit HIV-1 transfer from immature dendritic cells to human primary CD4 T-lymphocytes
por: Xu, K, et al.
Publicado: (2009)

Curcumin Enhances the Antitumoral Effect Induced by the Recombinant Vaccinia Neu Vaccine (rV-neuT) in Mice with Transplanted Salivary Gland Carcinoma Cells
por: Focaccetti, Chiara, et al.
Publicado: (2020)

Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate
por: Visciano, Maria Luisa, et al.
Publicado: (2013)

Automated image-based assay for evaluation of HIV neutralization and cell-to-cell fusion inhibition
por: Sheik-Khalil, Enas, et al.
Publicado: (2014)

P04-14. Sequential HIV-1 isolates from infected individuals reveals emergence of neutralization sensitive HIV-1 strains in the course of infection
por: Nyambi, PN, et al.
Publicado: (2009)

P04-22. Multispecific monoclonal antibodies bind to primary human macrophages and induce the production of protective chemokines, MIP-1α and MIP-1β
por: Weaver, KL, et al.
Publicado: (2009)

P04-55 LB. Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes
por: Zolla-Pazner, S, et al.
Publicado: (2009)

P11-20. HIV-1 gp41-specific mucosal IgAs from highly exposed but IgG seronegative women block HIV-1 epithelial transcytosis and neutralize CD4+ cell infection
por: Tudor, D, et al.
Publicado: (2009)

Antibody-Based HIV-1 Vaccines: Recent Developments and Future Directions: A summary report from a Global HIV Vaccine Enterprise Working Group
por: Montefiori, David, et al.
Publicado: (2007)

P05-04. Neutralizing antibodies induced by immunization with liposomal gp41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes
por: Matyas, GR, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_9c9b99hbklmt3c1ok1mn31fngo